ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

New Recommendations made For Radiation Protection Standards

August 14, 1987

In Brief: Interim Money Bill Passes; NCI Can Start Awarding Grants, Contract With 1980 funds, Until Nov. 20

October 26, 1979

NIH Strategic Plan To be Unveiled In San Antonio

January 31, 1992

Choice Of Reconstruction Can Depend On Who Consults

October 29, 2010

Research Opportunities In Pancreas Cancer Described; Top Priority Set

December 21, 1973

Central Europe Faces Massive Public Education, Environmental Problems, Related To Cancer

August 23, 1991